Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn, Julián Panés, Bruce E. Sands, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 50, Iss. 10, pp. 1068-1076
Open Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Ulcerative colitis
Taku Kobayashi, Britta Siegmund, Catherine Le Berre, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 1076
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine, Stefanos Bonovas, Johan Burisch, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 1, pp. 2-17
Closed Access | Times Cited: 652
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka, Taku Kobayashi, Fumiaki Ueno, et al.
Journal of Gastroenterology (2018) Vol. 53, Iss. 3, pp. 305-353
Open Access | Times Cited: 633
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 6, pp. 489-526
Open Access | Times Cited: 361
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
Pablo A. Olivera, Juan S. Lasa, Stefanos Bonovas, et al.
Gastroenterology (2020) Vol. 158, Iss. 6, pp. 1554-1573.e12
Open Access | Times Cited: 260
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
Ulcerative colitis: an update
Jonathan Segal, Jean‐Frédéric LeBlanc, Ailsa Hart
Clinical Medicine (2021) Vol. 21, Iss. 2, pp. 135-139
Open Access | Times Cited: 221
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 11, pp. 1400-1413
Open Access | Times Cited: 186
Cytokines in inflammatory bowel diseases – Update 2020
Moritz Leppkes, Markus F. Neurath
Pharmacological Research (2020) Vol. 158, pp. 104835-104835
Closed Access | Times Cited: 151
New Therapeutics for Ulcerative Colitis
Robert Hirten, Bruce E. Sands
Annual Review of Medicine (2021) Vol. 72, Iss. 1, pp. 199-213
Closed Access | Times Cited: 109
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
Ashwin N. Ananthakrishnan, Gilaad G. Kaplan, Çharles N. Bernstein, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 7, pp. 666-678
Closed Access | Times Cited: 83
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience
Sailish Honap, Desmond Chee, Thomas Chapman, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1385-1393
Closed Access | Times Cited: 104
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Pablo A. Olivera, Stéphane Zuily, Paulo Gustavo Kotze, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 12, pp. 857-873
Open Access | Times Cited: 104
Venous thromboembolism in inflammatory bowel disease
Kimberly Cheng, Adam S. Faye
World Journal of Gastroenterology (2020) Vol. 26, Iss. 12, pp. 1231-1241
Open Access | Times Cited: 94
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 8, pp. 1592-1601.e3
Open Access | Times Cited: 92
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
William Damsky, Danielle Peterson, Julie Y. Ramseier, et al.
Journal of Allergy and Clinical Immunology (2020) Vol. 147, Iss. 3, pp. 814-826
Closed Access | Times Cited: 90
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
William J. Sandborn, Brian G. Feagan, Stephen B. Hanauer, et al.
Journal of Crohn s and Colitis (2021) Vol. 15, Iss. 7, pp. 1120-1129
Open Access | Times Cited: 88
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
María Chaparro, A Garre, Francisco Mesonero, et al.
Journal of Crohn s and Colitis (2020) Vol. 15, Iss. 1, pp. 35-42
Open Access | Times Cited: 86
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Vince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 9, pp. 880-888
Open Access | Times Cited: 76
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis
Stefan D. Holubar, Amy L. Lightner, Vitaliy Poylin, et al.
Diseases of the Colon & Rectum (2021) Vol. 64, Iss. 7, pp. 783-804
Open Access | Times Cited: 61
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
William J. Sandborn, Geert R. D’Haens, Bruce E. Sands, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 3, pp. 338-351
Open Access | Times Cited: 58
Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study
Gursimran Kochhar, Himsikhar Khataniar, Vipul Jairath, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 12
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
William J. Sandborn, Laurent Peyrin‐Biroulet, Daniel Quirk, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 20, Iss. 8, pp. 1821-1830.e3
Open Access | Times Cited: 64
Efficacy of JAK inhibitors in Crohn’s Disease
Gerhard Rogler
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. Supplement_2, pp. S746-S754
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top